investigated for actively bleeding patients. However, we currently do not know how to best store PLTs in the cold for extended periods of time. In this study, we investigate how storage in plasma and PLT additive solutions (PASs) affects PLT viability in vivo.
STUDY DESIGN AND METHODS:
Twenty normal subjects had a 2-unit hyperconcentrated apheresis PLT collection. One unit was stored at 4 C in plasma for 3 days ("control unit"), and the CSP "test" unit was stored for 10 or 15 days in plasma or 10 days in 35% plasma with either 65% Intersol or Isoplate. After storage, all units were radiolabeled and transfused into their donors.
RESULTS: For 10-day storage, both the plasma and the Intersol units had significantly better PLT recoveries than the Isoplate units (24% AE 8% vs. 11% AE 3% [55% AE 11% vs. 21% AE 8% as percentage of control data], p = 0.002; and 18% AE 4% vs. 11% AE 3% [43% AE 6% vs. 21% AE 8% as percentage of control data], p = 0.004, respectively). There was a trend for lower PLT recoveries with Intersol compared to plasma (p = 0.056). PLT survivals and most in vitro measurements did not differ significantly among the units.
CONCLUSIONS: While the in vitro variables suggest
largely comparable results between plasma and PASs, in vivo recoveries were higher with plasma compared with both Intersol and Isoplate (p = 0.057 and p = 0.002, respectively). Whether this difference leads to clinically relevant differences in hemostatic efficacy remains to be determined.
patient populations could lead to both greater PLT availability and fewer outdates. When first introduced, PLT transfusions were predominantly used for the prophylactic transfusion support of hematology/oncology patients with hypoproliferative thrombocytopenia. These patients benefit from prolonged posttransfusion PLT survivals to decrease transfusion frequency. However, a recent analysis showed that as many as 50% of the PLTs transfused are given to non-hematology/oncology patients (i.e., trauma, surgery, intensive care unit, and general medicine patients) who often require only short-term hemostatic support. 10 CSPs corrected the bleeding time quicker than RSPs in patients with thrombocytopenia. 8 However, the data on in vivo efficacy of 4 C-stored PLTs are not uniformly in favor of 4 C storage. We previously showed that the majority of bleeding time measurements in patients with thrombocytopenia transfused with CSPs remained markedly prolonged, while most measurements in the control group (stored at 22 C) improved. 11 In addition, Filip Interestingly, patients who received cold-stored whole blood had significantly better aggregometry responses than RSPcontaining reconstituted whole blood. 13 Preliminary analysis of an ongoing Norwegian randomized, pilot trial in openheart surgery patients showed that patients who received up to 7-day-stored CSPs in a PLT additive solution (PAS; T-PAS, Terumo BCT) had significantly reduced postoperative blood loss with CSPs compared with RSPs.
14 At present, the Food and Drug Administration (FDA) allows transfusion of 3-day CSPs (whole blood-derived pooled PLTs or apheresis PLTs) only for actively bleeding patients. 15 CSPs have not been widely utilized presumably due to a lack of data suggesting superior efficacy in the target population of bleeding patients. Furthermore, the 3-day storage limit is even shorter than the limit for RSPs, thus offering even less flexibility. Studies to prolong storage time to 5 days and now 7 days with additional bacterial testing were only performed on RSPs because of the reduced in vivo viability of CSPs. PLT storage in PAS have been shown to allow for prolongation of the storage time in RSP storage studies. 16 At present, only two PASs are licensed by the FDA for room temperature storage, and they have not been widely adopted. 5, 14, 16 It is unknown how PAS may affect in vivo viability of PLTs stored at 4 C. In this study, we investigated the in vivo viability of autologous radiolabeled extended CSPs in plasma versus PAS in normal subjects along with in vitro tests currently required by the FDA for PLT licensing.
MATERIALS AND METHODS

Preparation of control and test PLTs
A double hyperconcentrated apheresis PLT unit was collected from 20 healthy adult subjects using an automated blood collection system (Trima Accel, Terumo BCT). After collection, the unit was split into two equal portions, and 1 unit was resuspended in 100% plasma for 3-day 4 C storage (control 
Radiolabeling of stored PLTs
Nineteen of 20 subjects were available for in vivo assessment. One subject did not return for the autologous transfusions. PLTs were radiolabeled as previously described, following the detailed Biomedical Excellence for Safer Transfusion (BEST) Collaborative protocol. 17 In brief, indium ( 111 In, Anazao) was used to label both control and test PLTs because per our preliminary experiments, the other available isotope, chromium, demonstrated very poor uptake of 51 Cr by refrigerated PLTs (data not shown). The 111 In-radiolabeled Day 3 CSPs were largely undetectable by Day 10, and therefore reuse of the same isotope to measure both control and test CSPs was considered feasible. Additionally, we collected a preinfusion radioactivity sample before the "test" transfusion to account for any possible residual 111 In activity after each subject's control transfusion and adjusted our calculations accordingly. On Day 3, the subject received an 111
In-radiolabeled aliquot of their control CSP unit. Follow-up samples from the subject were collected approximately 2 hours postinfusion and on Days 1 (×2, 2-10 hr apart), 2, 3, 4, and 5 to calculate recovery and survival of the subject's 3-day-stored PLTs.
The test CSPs in 100% plasma or PAS and plasma were initially stored for 10 days, and another group of subjects had their PLTs stored in 100% plasma for 15 days. After the test units were stored, an aliquot of their test units was obtained for 111 In labeling and subsequently transfused.
Follow-up samples, as above, were collected to calculate PLT recovery and survival of the test PLTs. These studies allowed direct comparisons of the same subject's control 3-day CSPs versus 10-or 15-day test-stored CSPs. Comparisons were further facilitated as both control and test PLTs were labeled with the same isotope.
In vitro PLT measurements
Platelet counts of collected products were performed on the day after collection to allow PLT disaggregation that might have occurred during collection and at the end of storage using a hematology analyzer (ABX, ABX Diagnostics). PLT yields were calculated by multiplying the PLT count times the volume of the PLT unit. After storage, in vitro measurements of glucose and lactate concentration and pH at 4 C
were measured with a commercially available blood gas instrument (ABL Flex 805, Radiometer Medical). Annexin V binding, P-selectin expression, microparticle quantification, and mean PLT volume were performed by flow cytometry (FACSCalibur, Beckman Coulter) as previously described. 18 The following antibodies were utilized: P-selectin CD62P-FITC (BD Biosciences), GPIbα-PE (BD Biosciences), and annexin V-FITC (BD Biosciences).
Statistical analysis
Based on our previous study, which evaluated extended room-temperature storage with PASs, 16 we calculated an effect size of approximately 2 for PLT recoveries between different PAS and plasma and different time points. Based on this a sample size of n = 5 was calculated to be required to provide 80% power to detect a significant difference between plasma and PAS (t test, unpaired, two-tailed α p = 0.05). We therefore planned to enroll five subjects per group and then assess for significance. We found results in the Isoplate group to be significantly lower with a small standard deviation (SD) and comparable or lower coefficient of variation compared to the other groups and therefore decided to terminate this group early with only three subjects evaluated. Results are reported as mean AE 1SD, and significance was assessed by unpaired, two-tailed t test, unless otherwise indicated. A p value equal to or less than 0.05 was considered significant.
RESULTS
Total PLT yield after storage
Poststorage PLT counts of the "control" units averaged 3.57 × 10 11 AE 0.38 × 10 11 after storage (99% AE 3% of prestorage values). No significant differences in PLT yields between PAS and plasma-stored PLTs were seen after 3 days , respectively (80 AE 7, 107 AE 12, 90 AE 39, and 72% AE 14% of prestorage values). We found a significant reduction after 10-and 15-day storage in plasma when compared to 10-day PAS Intersol-stored PLTs (p = 0.001 and p = 0.002, respectively). PLT yields of 10-day plasmastored, Intersol-stored, and 15-day plasma-stored did not differ significantly when compared to 10-day Isoplate-stored PLTs either absolute or as percentage of 3-day CSPs (Table 1, Fig. 1B ).
In vitro PLT measurements
As expected, glucose levels were significantly lower in either Intersol or Isoplate PAS compared to plasma-stored units ( Fig. 2A; 10- Fig. 2B ; p = 0.012). Markers indicating membrane orientation changes with phosphatidylserine exposure (% annexin V binding; Fig. 2C ) only showed a significant difference between Intersol and 15-day plasma (p = 0.034; Fig. 2C-10- , respectively), but there was no significant difference between plasma and PASs at 10 days of storage. For all PLT activation variables there was either a trend or a significantly higher value in 15-day plasma-stored units compared with 10-day plasma-stored units indicating continuous in vitro activation of PLTs in plasma.
In vivo PLT viability
For the 3-day control units (n = 19), poststorage PLT recoveries averaged 43% AE 11% and survivals 2 AE 0.4 days. For the test 10-day plasma, Intersol, Isoplate, and 15-day plasma units, poststorage recoveries averaged 24 AE 8, 18 AE 4, 8 AE 2, and 11% AE 3%, respectively (55 AE 11, 43 AE 6, 21 AE 8, and 29% AE 3%, respectively, of the same subject's 3-day control data; Fig. 3A) . We found the recovery of 10-day Isoplate and 15-day-stored plasma PLTs to be significantly lower compared with both 10-day plasma and Intersol-stored PLTs ( Fig. 3A ; p = 0.002 and p = 0.004 for 10 day Isoplate vs. 10-day plasma and Intersol, respectively, as well as p = 0.001 and p = 0.002 for 15-day plasma vs. 10-day plasma and Intersol, respectively). Interestingly, there was no significant difference between the recoveries of 10-day Intersol-and plasma-stored PLTs, although there was a trend for a lower recovery with Intersol ( Fig. 3A ; p = 0.057). Notably, Isoplate-stored PLTs showed significantly lower recoveries compared with Intersol-stored PLTs (p = 0.004). Posttransfusion survivals for the 10-day CSPs in plasma, Intersol, Isoplate, and 15 days in plasma averaged 1.2 AE 0.3, 1.1 AE 0.3, 0.9 AE 0.8, and 0.7 AE 0.2 days, respectively (59 AE 12, 56 AE 8, 48 AE 42, and 37% AE 7%, respectively, of the same subject's 3-day data; Fig. 3B ). PLT in vivo survival studies showed a significantly lower survival with PLTs stored in plasma for 15 days compared to any of the 10-day-stored PLTs ( Fig. 3B ; p = 0.01), but there were no significant differences among the 10-day-stored PLT groups.
DISCUSSION
Our study has four major findings: First, the PLT yield is significantly lower in plasma compared with PLTs stored in Intersol. Second, all CSPs are metabolically active and consume glucose, produce lactate, and show signs of increasing preactivation. Third, different PASs can yield significantly different in vivo results which cannot be predicted by their in vitro results. In this study, Isoplate showed a significantly lower recovery and a significantly lower PLT yield compared with Intersol, even though both have in vitro variables mostly in the same range. Finally, PLT recovery appears to be better in plasma compared with PASs, even though the PLT yield in vitro is significantly higher with Intersol compared with plasma. In vivo survival beyond Day 1 is likely not a major factor for CSPs, since the current target patient population for use of these PLTs are those with active bleeding, who are in need of PLTs to facilitate immediate localized hemostasis. PLT survivals did not differ among any of the 10-day CSPs in either plasma or PAS but was significantly less at 15 days in plasma.
Previous in vivo animal imaging studies suggest that hemostasis and local clot formation are processes that require minutes to hours and are not accomplished within seconds. 19, 20 In addition, the time frame required to complete major surgery itself is likely several hours. We therefore speculate that the 2-hour in vivo PLT recovery and the 1-day survival time point are likely the most important readouts for CSPs targeted for actively bleeding patients. One of our major findings is that there are significant differences between PASs for 10-day cold storage. While PLTs collected in Intersol showed recoveries that were not significantly different from that of plasma (p = 0.057), Isoplate showed significantly lower recoveries (p = 0.002). Previous studies suggest that PLT function is better preserved during cold storage in PAS and that there is less PLT aggregate formation in PAS compared with plasma. 5 We saw a lower PLT yield in plasma compared with PASs, but overall PLT recoveries were better in plasma compared with PAS. This either suggests that any potential aggregates that pass the bedside transfusion filter disaggregate in vivo and are of no clinical significance or that the aggregates are filtered out by the transfusion filter and PLTs that pass the bedside transfusion filter have a higher recovery compared with PAS-stored PLTs. It should also be emphasized that while one group reported visible aggregates in PLT units stored in plasma at 4 C, 5 we did not see any visible aggregates in our plasma-stored units. The only evidence for microaggregates in our study is based on the lower PLT yield in plasma versus PAS. However, we have preliminary data to suggest that this loss is in part due to loss of PLTs that adhere to the bag walls (data not shown).
We found glucose significantly lower in PAS plus glucose solutions compared with plasma alone. The removal of plasma (which contains glucose) during preparation of the PAS plus plasma units was likely the reason for lower glucose levels. Lower glucose in PAS was also likely the reason for the lower lactate, since removal of plasma with glucose deprived them of the essential energy source. It is also possible that PLTs in PAS are less metabolically active compared with PLTs stored in plasma; however, this will require further investigation.
A recently presented randomized Norwegian pilot study showed overall less blood loss in cardiac surgery patients after chest closure with CSPs stored in the PAS T-PAS (Terumo BCT) compared with RSPs. 14 We did not investigate T-PAS since it is currently not available in the United States. Better in vivo function measured by reduced blood loss in surgery patients has yet to be demonstrated with plasma-stored CSPs. Should CSPs be considered for transfusion support in massively bleeding patients, the additional plasma in the plasma-stored unit may be of importance. Recent studies have suggested that a higher plasma-to-RBC ratio (1:1:1; plasma, PLTs, and RBCs, respectively) could be beneficial in trauma patents. 21 PLT units in plasma are simpler to prepare than units that require replacement of plasma with PAS in a very specific ratio, a significant factor given that these PLTs are currently targeted as a future primary choice for blood banks in remote locations and far forward military scenarios. Patients who are in need of functional PLTs are frequently coagulopathic as well and could benefit from the additional plasma in the PLT unit, and the minor PLT loss due to microaggregates during storage in plasma may not outweigh the loss of plasma when opting for the replacement with PAS. More studies are needed to further investigate PASs for cold storage that are currently licensed for room temperature (Isoplate and Intersol) and newer PAS solutions including T-PAS, which is on a path to licensure in the United States. Our study has limitations, including the collection of PLTs in Intersol and Isoplate on the Trima system (Trima is licensed for use with Isoplate, while Intersol requires collection with the Fenwal Amicus system [Fresenius Kabi]). While it is possible that this has influenced our findings, we believe that it is highly unlikely that this was a major determinant in this study. Another limitation is that we use recovery and survival studies and in vitro PLT variables and cannot make any claims about in vivo function. We need large clinical trials or bleeding time studies in humans with a room-temperature comparator to settle the debate if the in vivo function of CSPs is indeed better at preventing and treating blood loss. Finally, one limitation arises from a lack of a current standard-of-care (room temperature-stored) control; however, recovery and survival studies have been performed extensively on RSPs and in vivo recovery and survival are known to be superior to CSPs.
In summary, our study is the first to compare recovery and survival of CSPs in PAS and plasma in healthy human subjects. We found that both 65% Intersol/35% plasma and 100% plasma CSPs have potential advantages over the other; however, more studies especially in actively bleeding patients to demonstrate hemostatic efficacy are needed.
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